Article Versions Notes

Oh Y, Lee J-S, Lee JS, Park JH, Kim HS, Yoon S. JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells. International Journal of Molecular Sciences. 2022; 23(9):4597. https://doi.org/10.3390/ijms23094597

Oh, Yunmoon, Jin-Sol Lee, Ji Sun Lee, Jae Hyeon Park, Hyung Sik Kim, and Sungpil Yoon. 2022. "JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells" International Journal of Molecular Sciences 23, no. 9: 4597. https://doi.org/10.3390/ijms23094597

Oh, Y., Lee, J.-S., Lee, J. S., Park, J. H., Kim, H. S., & Yoon, S. (2022). JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells. International Journal of Molecular Sciences, 23(9), 4597. https://doi.org/10.3390/ijms23094597